Biotechnology
Origin Agritech Announces Breakthrough in High-Yield Corn Production Through Gene Editing
Inbred Line Yield Increased Over 50% in Trials BEIJING, March 20, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced a major breakthrough in corn production technology. Building on the Company's...
2024-03-20 20:00
1536
SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential
SHANGHAI, March 19, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative-driven biopharmaceutical company with entire industry chain, presented the clinical study data of the 9MW2821 for patients with cervical cancer as focused plenary oral presentation at the Society of Gynecologic Oncology ...
2024-03-19 22:00
1568
Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study
* The world's first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy; * The response rate increased by 89.4% compared to the placebo control group, with a low incidence of adverse events; * The China new drug application submiss...
2024-03-19 10:24
1381
Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC
SHANGHAI, March 18, 2024 /PRNewswire/ -- Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement. BioGeometry is a digital biology pioneer company that specializes in AI-driven protein design and R&D platform. Sanyou Bio is a world-leading high-tec...
2024-03-19 08:00
1303
Lunit Expands Presence in Europe: to Deliver AI-powered Cancer Screening Solution to France and Portugal
* New supply contract to bring Lunit INSIGHT CXR to TeleDiag in France and Lunit INSIGHT MMG to the Central region branch of the Portuguese League Against Cancer SEOUL, South Korea, March 18, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diag...
2024-03-18 21:00
1839
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time
* Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6% * Net Profit Attributable to the Owners of the Company[1] Increased 9.0% to RMB9,607 Million; Diluted Earnings per Share (EPS) Increased 14.9% to RMB3.24 * Adjusted Non-IFRS Net Profit Att...
2024-03-18 20:32
2595
Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis
SHENZHEN, China, March 18, 2024 /PRNewswire/ -- On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as "chipscreen biosciences", stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for non-alcoholic steatoh...
2024-03-18 19:25
1730
KeChow Pharma Announces NMPA Approval of Tunlametinib (HL-085) as the First Targeted Therapy for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1
-- Tunlametinib is poised to be a potential best-in-class MEK inhibitor based on positive data from the pivotal Phase 2 study SHANGHAI, March 18, 2024 /PRNewswire/ -- KeChow Pharma, a commercial-stage pharmaceutical company focused on developing and commercializing differentiated small molecule ...
2024-03-18 18:02
1380
ImmVira's oncolytic product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment
SHENZHEN, China, March 15, 2024 /PRNewswire/ -- ImmVira has recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for oncolytic virus product MVR-T3011 IT (intratumoral injection) for the treatment of recurrent or metastatic head and neck squamous ...
2024-03-15 13:56
1625
Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates
ZHUHAI, China, March 15, 2024 /PRNewswire/ -- On March 14, 2024, Biotheus Inc. (Biotheus), a clinical-stage biotech company focusing on the discovery and development of biologics for oncology and inflammatory diseases, and Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma,03692.HK), China's le...
2024-03-15 12:34
1540
I-Mab Reports Full Year 2023 Financial Results and Business Update
* Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end ofMarch 2024 * Uliledlimab (CD73 antibody) on track to file an IND in combination with chemotherapy and checkpoint inh...
2024-03-15 05:00
3428
D3 Bio Appoints Dr. Antoine Yver as Independent Board Member
SHANGHAI, March 14, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs, welcomesAntoine Yver, MD. ,MSc. as the new independent board member, effectiveMarch 4, 2024. Dr. Yver has 34 years of e...
2024-03-14 22:30
1877
Study of Kintor's c-Myc Degrader Published in Subsidiary Journal of Nature
SUZHOU, China, March 14, 2024 /PRNewswire/ -- Kintor Pharmaceutical Limited (" Kintor Pharma", HKEX: 9939.HK), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announces that Kintor and its cooperative partner had published an article namedMY...
2024-03-14 12:22
1581
YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024
SHANGHAI, March 13, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech
company pioneering inin vivo gene editing therapies, today announced
participation in TIDES Asia 2024, March 19th to 21st, 2024, at the Westin
Miyako Kyoto inKyoto, Japan.
TIDES Asia
2024-03-13 20:00
1513
Sanyou Biopharmaceuticals Launches Advanced Intelligent R&D Service Platform
SHANGHAI, March 12, 2024 /PRNewswire/ -- Sanyou Biopharmaceutical Co., Ltd. is delighted to announce the official launch of the "Sanyou Intelligent Innovative Biologics R&D Service Platform," representing a transformative advancement in biopharmaceutical research and development. Our platform en...
2024-03-13 09:00
1646
Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting
SHANGHAI, March 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of three preclinical studies as poster presentation at the AACR Annual Meeting to be held inSan Diego, USA, from April 5...
2024-03-12 22:00
1879
GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%
R&D Innovation to Lead the Future, Deepening Customer Value Creation * Sustained High Revenue Growth: GenScript Group's five-year CAGR stands at an impressive 30%, with a strong global operation and stable cash flow. In 2023, the group's best-in-class cell therapy product CARVYKTI®, achieved sa...
2024-03-12 20:15
2709
Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD
SAN DIEGO, March 12, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, ...
2024-03-12 20:00
1592
Mabwell to Present ADC Platform IDDC™ and the Latest Study Results of Multiple Novel ADCs at the 14th World ADC London
SHANGHAI, March 11, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present its next generation ADC platform IDDC™ and the latest study results of multiple novel ADCs (9MW2821, 7MW3711, 9MW2921) developed...
2024-03-11 22:00
1525
Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout
BOSTON, March 11, 2024 /PRNewswire/ -- Medicilon, a one-stop pharmaceutical preclinical research and developmentCRO can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and efficiently with fast initiation times.Over the past 20 year...
2024-03-11 20:30
1588
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5203
